trending Market Intelligence /marketintelligence/en/news-insights/trending/fKdfcSeHcv7jGXiIBJkBDg2 content esgSubNav
In This List

MediciNova's ALS treatment orphan-drug designated in Europe

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

Blog

Commercial Banking Newsletter June Edition - 2022


MediciNova's ALS treatment orphan-drug designated in Europe

The European Commission designated as an orphan drug MediciNova Inc.'s MN-166 treatment for amyotrophic lateral sclerosis, or ALS.

The development offers potential benefits including protocol assistance, fee reductions and a 10-year market exclusivity once the medicine is introduced in the European market.

The drug is also designated as an orphan drug for ALS in the U.S. and is marketed in Japan and Korea to treat post-stroke complications and bronchial asthma.